PRESS RELEASEAB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE ...
The MarketWatch News Department was not involved in the creation of this content. STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a ...
At baseline, approximately 92% of patients were MRD-negative and had excellent outcomes, with a 5-year distant recurrence-free interval (DRFI) of 93%. Measured starting at EOT, MRD-negative patients ...
NEW YORK, Dec. 4, 2025 /PRNewswire/ -- PreciseDx, the leading innovator behind PreciseBreast, a novel AI digital pathology test, announces the upcoming presentation of three abstracts that further ...
At a median follow-up of 106 months, cumulative incidence of metastasis was 4.8% in the chRCC cohort, compared to 0% in the oncocytoma and ORNLMP cohorts. Oncocytomas and oncocytic neoplasms of low ...
After 5 years, Kisqali ® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival 1 Kisqali remains the only CDK4/6 inhibitor ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients ...
Recurrence risk for stage II to III colon cancer falls below 0.5% 6 years posttreatment, suggesting a potential cure definition. The study analyzed data from 15 phase 3 trials, involving 35,213 ...
German investigators carried out raids in relation to Northern Data AG, a technology firm backed by Tether Holdings Ltd. The raids relate to an older investigation by Swedish prosecutors into whether ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback